Linde, Philipp, Baues, Christian, Wegen, Simone, Trommer, Maike, Quaas, Alexander, Rosenbrock, Johannes, Celik, Eren, Marnitz, Simone, Bruns, Christiane J., Fischer, Thomas, Schomaecker, Klaus, Wester, Hans-Juergen, Drzezga, Alexander ORCID: 0000-0001-6018-716X, van Heek, Lutz and Kobe, Carsten (2021). Pentixafor PET/CT for imaging of chemokine receptor 4 expression in esophageal cancer - a first clinical approach. Cancer Imaging, 21 (1). LONDON: BMC. ISSN 1470-7330

Full text not available from this repository.

Abstract

Background Expression of CXCR4, a chemokine (C-X-C motif) receptor that plays a central role in tumor growth and metastasis of circulating tumor cells, has been described in a variety of solid tumors. A high expression of CXCR4 has a prognostic significance with regard to overall and progression-free survival and offers a starting point for targeted therapies. In this context, [68]Ga-Pentixafor-Positron Emission Tomography/Computer Tomography (PET/CT) offers promising possibility of imaging the CXCR4 expression profile. We set out to compare a [18F] fluorodeoxyglucose (FDG)-PET/CT and a [68Ga]Pentixafor-PET/CT in (re-)staging and radiation planning of patients with localized esophageal cancer. Materials and methods In this retrospective analysis, ten patients, with adeno- or squamous cell carcinoma of the esophagus (n = 3 and n = 7, respectively), which were scheduled for radio (chemo) therapy, were imaged using both Pentixafor and FDG PET/CT examinations. All lesions were visually rated as Pentixafor and FDG positive or negative. For both tracers, SUVmax was measured all lesions and compared to background. Additionally, immunohistochemistry of CXCR4 was obtained in patients undergoing surgery. Results FDG-positive tumor-suspicious lesions were detected in all patients and a total of 26 lesions were counted. The lesion-based analysis brought equal status in 14 lesions which were positive for both tracers while five lesions were FDG positive and Pentixafor negative and seven lesions were FDG negative, but Pentixafor positive. Histopathologic correlation was available in seven patients. The CXCR4 expression of four non-pretreated tumour lesion samples was confirmed immunohistochemically. Conclusion Our data shows that additional PET/CT imaging with Pentixafor for imaging the CXCR4 chemokine receptor is feasible but heterogeneous in both newly diagnosed and pretreated recurrent esophageal cancer. In addition, the Pentixafor PET/CT may serve as complementary tool for radiation field expansion in radiooncology.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Linde, PhilippUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Baues, ChristianUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Wegen, SimoneUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Trommer, MaikeUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Quaas, AlexanderUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Rosenbrock, JohannesUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Celik, ErenUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Marnitz, SimoneUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Bruns, Christiane J.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Fischer, ThomasUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Schomaecker, KlausUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Wester, Hans-JuergenUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Drzezga, AlexanderUNSPECIFIEDorcid.org/0000-0001-6018-716XUNSPECIFIED
van Heek, LutzUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kobe, CarstenUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-570685
DOI: 10.1186/s40644-021-00391-w
Journal or Publication Title: Cancer Imaging
Volume: 21
Number: 1
Date: 2021
Publisher: BMC
Place of Publication: LONDON
ISSN: 1470-7330
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
Oncology; Radiology, Nuclear Medicine & Medical ImagingMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/57068

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item